<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>SurvAgent: Hierarchical CoT-Enhanced Case Banking and Dichotomy-Based Multi-Agent System for Multimodal Survival Prediction - Health AI Hub</title>
    <meta name="description" content="SurvAgent introduces the first hierarchical Chain-of-Thought (CoT)-enhanced multi-agent system designed for multimodal survival prediction in cancer, specifical">
    <link rel="icon" type="image/svg+xml" href="../favicon.svg">
    <link rel="icon" type="image/png" sizes="32x32" href="../favicon-32x32.png">
    <link rel="icon" type="image/png" sizes="16x16" href="../favicon-16x16.png">
    <link rel="stylesheet" href="../styles.css">
</head>
<body>
    <header>
        <div class="container">
            <div class="breadcrumb">
                <a href="../index.html">‚Üê Back to all papers</a>
                <a href="../index.html" class="home-btn">üè† Home</a>
            </div>
        </div>
    </header>

    <main class="container paper-detail">
        <article>
            <h1>SurvAgent: Hierarchical CoT-Enhanced Case Banking and Dichotomy-Based Multi-Agent System for Multimodal Survival Prediction</h1>

            <div class="paper-metadata">
                <div class="meta-row">
                    <strong>arXiv ID:</strong> <a href="http://arxiv.org/abs/2511.16635v1" target="_blank">2511.16635v1</a>
                </div>
                <div class="meta-row">
                    <strong>Published:</strong> 2025-11-20
                </div>
                <div class="meta-row">
                    <strong>Authors:</strong> Guolin Huang, Wenting Chen, Jiaqi Yang, Xinheng Lyu, Xiaoling Luo, Sen Yang, Xiaohan Xing, Linlin Shen
                </div>
                <div class="meta-row">
                    <strong>Categories:</strong> cs.CV, cs.CL
                </div>
                <div class="meta-row">
                    <strong>Relevance Score:</strong> 0.98 / 1.00
                </div>
            </div>

            <div class="action-buttons">
                <a href="http://arxiv.org/abs/2511.16635v1" target="_blank" class="btn btn-primary">View on arXiv</a>
                <a href="https://arxiv.org/pdf/2511.16635v1" target="_blank" class="btn btn-primary">Download PDF</a>
            </div>

            <section class="paper-section">
                <h2>Summary</h2>
                <p class="summary-text">SurvAgent introduces the first hierarchical Chain-of-Thought (CoT)-enhanced multi-agent system designed for multimodal survival prediction in cancer, specifically addressing the lack of transparency, multimodal data integration, effective ROI exploration, and experiential learning in existing methods. It constructs a case bank with CoT-reasoned reports from WSI and gene data, followed by a multi-expert inference stage using retrieval-augmented generation (RAG) and progressive interval refinement, demonstrating superior performance and explainability in precision oncology.</p>
            </section>

            <section class="paper-section">
                <h2>Medical Relevance</h2>
                <p>Accurate and transparent survival prediction is paramount for effective cancer prognosis and personalized treatment planning. SurvAgent's ability to integrate multimodal data (pathology and genetics) with explainable AI reasoning enhances clinicians' trust and provides actionable insights, moving towards true precision oncology.</p>
            </section>

            
            <section class="paper-section">
                <h2>AI Health Application</h2>
                <p>SurvAgent is a medical AI application designed for multimodal survival prediction, specifically for cancer prognosis and treatment planning. It leverages hierarchical AI agents to integrate pathology images and genomic data, providing explainable predictions. This aims to enhance clinical decision support in precision oncology by offering transparent, AI-driven insights into patient outcomes.</p>
            </section>
            

            <section class="paper-section">
                <h2>Key Points</h2>
                <ul class="key-points">
                    
                    <li>Addresses critical limitations of existing survival prediction methods and pathology agents, including lack of transparency, inability to integrate multimodal data (WSI and genes), ineffective region-of-interest exploration, and failure to leverage experiential learning.</li>
                    
                    <li>Introduces SurvAgent, a novel hierarchical CoT-enhanced multi-agent system, as the first of its kind for multimodal survival prediction, aiming for clinical explainability.</li>
                    
                    <li>Stage 1, WSI-Gene CoT-Enhanced Case Bank Construction, employs hierarchical analysis for pathology images (Low-Magnification Screening, Cross-Modal Similarity-Aware Patch Mining, Confidence-Aware Patch Mining) and Gene-Stratified analysis across six functional gene categories.</li>
                    
                    <li>This stage generates structured, CoT-reasoned reports for both pathology and gene data, storing complete analytical processes to facilitate experiential learning from historical cases.</li>
                    
                    <li>Stage 2, Dichotomy-Based Multi-Expert Agent Inference, retrieves similar historical cases using RAG and integrates multimodal reports with expert predictions through a progressive interval refinement mechanism.</li>
                    
                    <li>Extensive experiments across five TCGA cohorts demonstrate SurvAgent's superior performance compared to conventional survival analysis methods, proprietary Multimodal Large Language Models (MLLMs), and other medical agents.</li>
                    
                    <li>Establishes a new paradigm for explainable AI-driven survival prediction, enhancing transparency and clinical utility in precision oncology for cancer prognosis and treatment planning.</li>
                    
                </ul>
            </section>

            <div class="two-column">
                <section class="paper-section">
                    <h2>Methodology</h2>
                    <p>SurvAgent operates in two stages: (1) WSI-Gene CoT-Enhanced Case Bank Construction, where pathology images undergo hierarchical analysis (low-magnification screening, cross-modal and confidence-aware patch mining), and gene data is processed via gene-stratified analysis across six functional categories. Both generate structured reports with CoT reasoning for experiential learning. (2) Dichotomy-Based Multi-Expert Agent Inference, which retrieves similar cases using Retrieval-Augmented Generation (RAG) and integrates multimodal reports with expert predictions through a progressive interval refinement process.</p>
                </section>

                <section class="paper-section">
                    <h2>Key Findings</h2>
                    <p>SurvAgent consistently outperforms conventional survival prediction methods, proprietary MLLMs, and existing medical agents across experiments on five distinct TCGA (The Cancer Genome Atlas) cohorts. This establishes its superiority in accurate and explainable multimodal survival prediction.</p>
                </section>
            </div>

            <section class="paper-section">
                <h2>Clinical Impact</h2>
                <p>By providing explainable AI-driven survival predictions, SurvAgent can significantly improve the transparency and reliability of cancer prognosis and treatment planning. This facilitates better-informed clinical decisions, enables more precise patient stratification, and supports the advancement of personalized medicine in precision oncology, potentially leading to improved patient outcomes.</p>
            </section>

            
            <section class="paper-section">
                <h2>Limitations</h2>
                <p>The abstract does not explicitly mention any limitations or caveats regarding SurvAgent itself, focusing instead on addressing the limitations of existing methods and other pathology agents.</p>
            </section>
            

            
            <section class="paper-section">
                <h2>Future Directions</h2>
                <p>Not explicitly mentioned in the abstract.</p>
            </section>
            

            <section class="paper-section">
                <h2>Medical Domains</h2>
                <div class="tags">
                    
                    <span class="tag">Oncology</span>
                    
                    <span class="tag">Pathology</span>
                    
                    <span class="tag">Cancer Genomics</span>
                    
                    <span class="tag">Prognostics</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Keywords</h2>
                <div class="tags">
                    
                    <span class="tag tag-keyword">Survival Analysis</span>
                    
                    <span class="tag tag-keyword">Multimodal AI</span>
                    
                    <span class="tag tag-keyword">Explainable AI</span>
                    
                    <span class="tag tag-keyword">Multi-Agent System</span>
                    
                    <span class="tag tag-keyword">Chain-of-Thought (CoT)</span>
                    
                    <span class="tag tag-keyword">Pathology</span>
                    
                    <span class="tag tag-keyword">Genomics</span>
                    
                    <span class="tag tag-keyword">Precision Oncology</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Abstract</h2>
                <p class="abstract">Survival analysis is critical for cancer prognosis and treatment planning, yet existing methods lack the transparency essential for clinical adoption. While recent pathology agents have demonstrated explainability in diagnostic tasks, they face three limitations for survival prediction: inability to integrate multimodal data, ineffective region-of-interest exploration, and failure to leverage experiential learning from historical cases. We introduce SurvAgent, the first hierarchical chain-of-thought (CoT)-enhanced multi-agent system for multimodal survival prediction. SurvAgent consists of two stages: (1) WSI-Gene CoT-Enhanced Case Bank Construction employs hierarchical analysis through Low-Magnification Screening, Cross-Modal Similarity-Aware Patch Mining, and Confidence-Aware Patch Mining for pathology images, while Gene-Stratified analysis processes six functional gene categories. Both generate structured reports with CoT reasoning, storing complete analytical processes for experiential learning. (2) Dichotomy-Based Multi-Expert Agent Inference retrieves similar cases via RAG and integrates multimodal reports with expert predictions through progressive interval refinement. Extensive experiments on five TCGA cohorts demonstrate SurvAgent's superority over conventional methods, proprietary MLLMs, and medical agents, establishing a new paradigm for explainable AI-driven survival prediction in precision oncology.</p>
            </section>

            
            <section class="paper-section">
                <h2>Comments</h2>
                <p>20 pages</p>
            </section>
            

            
        </article>
    </main>

    <footer class="container">
        <p><a href="../index.html">‚Üê Back to all papers</a></p>
    </footer>
</body>
</html>